Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL.

J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.

2.

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL.

Blood. 2014 Mar 27;123(13):2075-83. doi: 10.1182/blood-2014-01-547760. Epub 2014 Jan 27.

3.

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Ambati SR, Lopes EC, Kosugi K, Mony U, Zehir A, Shah SK, Taldone T, Moreira AL, Meyers PA, Chiosis G, Moore MA.

Mol Oncol. 2014 Mar;8(2):323-36. doi: 10.1016/j.molonc.2013.12.005. Epub 2013 Dec 15.

4.

Future therapies for the myeloproliferative neoplasms.

Scherber R, Mesa RA.

Curr Hematol Malig Rep. 2011 Mar;6(1):22-7. doi: 10.1007/s11899-010-0068-4. Review.

PMID:
21080242
5.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

6.

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.

Quintás-Cardama A, Verstovsek S.

Cancer. 2012 Feb 15;118(4):870-7. doi: 10.1002/cncr.26359. Epub 2011 Jul 15.

8.

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.

Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, O'Hare T, Deininger MW.

Exp Hematol. 2015 Jul;43(7):537-45.e1-11. doi: 10.1016/j.exphem.2015.03.006. Epub 2015 Apr 24.

9.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL.

Blood. 2010 Apr 8;115(14):2919-27. doi: 10.1182/blood-2009-04-218842. Epub 2010 Feb 12.

10.

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA.

PLoS One. 2006 Dec 20;1:e18.

11.

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative..

PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31.

12.

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL.

Nature. 2012 Sep 6;489(7414):155-9. doi: 10.1038/nature11303.

13.

Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.

Stein BL, Tiu RV.

J Interferon Cytokine Res. 2013 Apr;33(4):145-53. doi: 10.1089/jir.2012.0120. Review.

PMID:
23570380
14.

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.

Fiskus W, Verstovsek S, Manshouri T, Rao R, Balusu R, Venkannagari S, Rao NN, Ha K, Smith JE, Hembruff SL, Abhyankar S, McGuirk J, Bhalla KN.

Clin Cancer Res. 2011 Dec 1;17(23):7347-58. doi: 10.1158/1078-0432.CCR-11-1541. Epub 2011 Oct 5.

15.

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Patel AB, Vellore NA, Deininger MW.

Clin Cancer Res. 2016 Mar 1;22(5):1037-47. doi: 10.1158/1078-0432.CCR-15-0905. Review.

16.

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. doi: 10.1073/pnas.0903392106. Epub 2009 May 5.

17.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
18.
19.

Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?

Pardanani A, Tefferi A.

Leuk Lymphoma. 2014 Dec;55(12):2706-11. doi: 10.3109/10428194.2014.985159. Review.

PMID:
25520049
20.

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.

Michiels JJ, Berneman Z, Schroyens W, De Raeve H.

Acta Haematol. 2015;133(1):36-51. doi: 10.1159/000358580. Epub 2014 Aug 7. Review.

PMID:
25116092

Supplemental Content

Support Center